These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1040 related items for PubMed ID: 27769042

  • 1. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
    Dacic S, Villaruz LC, Abberbock S, Mahaffey A, Incharoen P, Nikiforova MN.
    Oncotarget; 2016 Dec 13; 7(50):82943-82952. PubMed ID: 27769042
    [Abstract] [Full Text] [Related]

  • 2. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
    Ma D, Wang Z, Yang L, Mu X, Wang Y, Zhao X, Li J, Lin D.
    Oncotarget; 2016 Sep 27; 7(39):64410-64420. PubMed ID: 27418132
    [Abstract] [Full Text] [Related]

  • 3. Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment.
    Li W, Zhang J, Guo L, Chuai S, Shan L, Ying J.
    J Thorac Oncol; 2017 Jan 27; 12(1):94-101. PubMed ID: 27614248
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
    Shi R, Varella-Garcia M, Li M, Ludkovski O, Danesh A, Ng C, Pham NA, Pugh T, Shepherd FA, Tsao MS.
    J Thorac Oncol; 2016 Dec 27; 11(12):2248-2252. PubMed ID: 27613526
    [Abstract] [Full Text] [Related]

  • 6. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM, Hensing T, Schrock AB, Allen J, Sanford E, Gowen K, Kulkarni A, He J, Suh JH, Lipson D, Elvin JA, Yelensky R, Chalmers Z, Chmielecki J, Peled N, Klempner SJ, Firozvi K, Frampton GM, Molina JR, Menon S, Brahmer JR, MacMahon H, Nowak J, Ou SH, Zauderer M, Ladanyi M, Zakowski M, Fischbach N, Ross JS, Stephens PJ, Miller VA, Wakelee H, Ganesan S, Salgia R.
    Oncologist; 2016 Jun 27; 21(6):762-70. PubMed ID: 27245569
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, Ribechini A, Cappuzzo F, Melfi F, Lucchi M, Mussi A, Fontanini G.
    Arch Pathol Lab Med; 2014 Nov 27; 138(11):1449-58. PubMed ID: 24885803
    [Abstract] [Full Text] [Related]

  • 9. Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Smuk G, Pajor G, Szuhai K, Morreau H, Kocsmár I, Kocsmár É, Pajor L, Kajtár B, Sárosi V, Lotz G, Tornóczky T.
    Lung Cancer; 2020 May 27; 143():80-85. PubMed ID: 32272316
    [Abstract] [Full Text] [Related]

  • 10. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies.
    Ilie MI, Bence C, Hofman V, Long-Mira E, Butori C, Bouhlel L, Lalvée S, Mouroux J, Poudenx M, Otto J, Marquette CH, Hofman P.
    Ann Oncol; 2015 Jan 27; 26(1):238-244. PubMed ID: 25344360
    [Abstract] [Full Text] [Related]

  • 11. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    McLeer-Florin A, Duruisseaux M, Pinsolle J, Dubourd S, Mondet J, Phillips Houlbracq M, Magnat N, Fauré J, Chatagnon A, de Fraipont F, Giaj Levra M, Toffart AC, Ferretti G, Hainaut P, Brambilla E, Moro-Sibilot D, Lantuejoul S.
    Lung Cancer; 2018 Feb 27; 116():15-24. PubMed ID: 29413046
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of crizotinib in a patient with ALK IHC-positive/FISH-negative metastatic lung adenocarcinoma.
    Rosoux A, Pauwels P, Duplaquet F, D'Haene N, Weynand B, Delos M, Menon R, Heukamp LC, Thunnissen E, Ocak S.
    Lung Cancer; 2016 Aug 27; 98():118-121. PubMed ID: 27393517
    [Abstract] [Full Text] [Related]

  • 13. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in Lung Adenocarcinoma.
    Jang JS, Wang X, Vedell PT, Wen J, Zhang J, Ellison DW, Evans JM, Johnson SH, Yang P, Sukov WR, Oliveira AM, Vasmatzis G, Sun Z, Jen J, Yi ES.
    J Thorac Oncol; 2016 Nov 27; 11(11):1891-1900. PubMed ID: 27343444
    [Abstract] [Full Text] [Related]

  • 14. [A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens].
    Wang Z, Wu X, Shi Y, Han X, Cheng G, Li L, Mu X, Zhang Y, Cui D, Zhang L, Fan Z, Zhu G, Ma L, Yang L, Di J, Liu D.
    Zhonghua Zhong Liu Za Zhi; 2015 Oct 27; 37(10):742-8. PubMed ID: 26813592
    [Abstract] [Full Text] [Related]

  • 15. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F.
    Cancer Treat Rev; 2014 Mar 27; 40(2):300-6. PubMed ID: 23931927
    [Abstract] [Full Text] [Related]

  • 16. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C, Shi X, Yang S, Zhao J, He Q, Jin Y, Yu X.
    Lung Cancer; 2019 May 27; 131():62-68. PubMed ID: 31027700
    [Abstract] [Full Text] [Related]

  • 17. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer.
    Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE, Varella-Garcia M.
    Cancer; 2012 Sep 15; 118(18):4486-94. PubMed ID: 22282074
    [Abstract] [Full Text] [Related]

  • 18. BIRC6-ALK, a Novel Fusion Gene in ALK Break-Apart FISH-Negative Lung Adenocarcinoma, Responds to Crizotinib.
    Shan L, Jiang P, Xu F, Zhang W, Guo L, Wu J, Zeng Y, Jiao Y, Ying J.
    J Thorac Oncol; 2015 Jun 15; 10(6):e37-9. PubMed ID: 26001147
    [No Abstract] [Full Text] [Related]

  • 19. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
    Hembrough T, Liao WL, Hartley CP, Ma PC, Velcheti V, Lanigan C, Thyparambil S, An E, Monga M, Krizman D, Burrows J, Tafe LJ.
    Clin Chem; 2016 Jan 15; 62(1):252-61. PubMed ID: 26585927
    [Abstract] [Full Text] [Related]

  • 20. Targeted next-generation-sequencing for reliable detection of targetable rearrangements in lung adenocarcinoma-a single center retrospective study.
    Velizheva NP, Rechsteiner MP, Valtcheva N, Freiberger SN, Wong CE, Vrugt B, Zhong Q, Wagner U, Moch H, Hillinger S, Schmitt-Opitz I, Soltermann A, Wild PJ, Tischler V.
    Pathol Res Pract; 2018 Apr 15; 214(4):572-578. PubMed ID: 29580750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.